You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Oct 2012

Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer

    View All Author Information


    Previous studies have suggested an association between [−2]proPSA expression and prostate cancer detection. Less is known about the usefulness of this marker in following patients with prostate cancer on active surveillance. Thus, we examined the relationship between [−2]proPSA and biopsy results in men enrolled in an active surveillance program.

    Materials and Methods:

    In 167 men from our institutional active surveillance program we used Cox proportional hazards models to examine the relationship between [−2]proPSA and annual surveillance biopsy results. The outcome of interest was biopsy reclassification (Gleason score 7 or greater, more than 2 positive biopsy cores or more than 50% involvement of any core with cancer). We also examined the association of biopsy results with total prostate specific antigen, %fPSA, [−2]proPSA/%fPSA and the Beckman Coulter Prostate Health Index phi ([−2]proPSA/free prostate specific antigen) × (total prostate specific antigen)½).


    While on active surveillance (median time from diagnosis 4.3 years), 63 (37.7%) men demonstrated biopsy reclassification based on the previously mentioned criteria, including 28 (16.7%) of whom had reclassification based on Gleason score upgrading (Gleason score 7 or greater). Baseline and longitudinal %fPSA, %[−2]proPSA, [−2]proPSA/%fPSA and phi measurements were significantly associated with biopsy reclassification, and %[−2]proPSA and phi provided the greatest predictive accuracy for high grade cancer.


    In men on active surveillance, measures based on [−2]proPSA such as phi appear to provide improved prediction of biopsy reclassification during followup. Additional validation is warranted to determine whether clinically useful thresholds can be defined, and to better characterize the role of %[−2]proPSA and phi in conjunction with other markers in monitoring patients enrolled in active surveillance.


    • 1 : Cancer Facts & Figures 2012. Atlanta: American Cancer Society2012. Google Scholar
    • 2 : Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem2003; 49: 253. Google Scholar
    • 3 : Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med2003; 52: 86. Google Scholar
    • 4 : Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res2001; 61: 957. Google Scholar
    • 5 : A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res2000; 60: 756. MedlineGoogle Scholar
    • 6 : Proenzyme PSA for the early detection of prostate cancer in the 2.5–4.0 ng/ml total PSA range: preliminary analysis. Urology2003; 61: 274. Google Scholar
    • 7 : Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol2003; 170: 2181. LinkGoogle Scholar
    • 8 : Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol2010; 57: 921. Google Scholar
    • 9 : A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol2011; 185: 1650. LinkGoogle Scholar
    • 10 : A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev2010; 19: 1193. Google Scholar
    • 11 : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol2004; 171: 2239. LinkGoogle Scholar
    • 12 : Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res2009; 15: 7316. Google Scholar
    • 13 : ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology2011; 77: 763. Google Scholar
    • 14 : Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol2002; 167: 1231. LinkGoogle Scholar
    • 15 : Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol2011; 29: 2185. Google Scholar
    • 16 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Crossref, MedlineGoogle Scholar
    • 17 : NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw2010; 8: 162. Google Scholar
    • 18 : Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health1999; 20: 145. Google Scholar
    • 19 : Attrition in longitudinal studies: How to deal with missing data. J Clin Epidemiol2002; 55: 329. Google Scholar
    • 20 : Comparing the predictive power of survival models using Harrell's c or Somers' D. Stata J2010; 10: 339. Google Scholar
    • 21 : Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2010; 28: 126. Google Scholar
    • 22 : Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst2006; 98: 355. Google Scholar
    • 23 : Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?. Cancer2010; 116: 1281. Google Scholar
    • 24 : Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst2006; 98: 1134. Google Scholar
    • 25 : Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol2010; 183: 1779. LinkGoogle Scholar
    • 26 : Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol2010; 183: 534. LinkGoogle Scholar
    • 27 : Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol2003; 170: 723. LinkGoogle Scholar
    • 28 : [−2]Proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol2008; 180: 539. LinkGoogle Scholar
    • 29 : [−2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol2010; 183: 1355. LinkGoogle Scholar
    • 30 : Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol2008; 179: 901. LinkGoogle Scholar